Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024

Business Wire

2024-10-31

ROCKVILLE, Md. & EDMONTON, Alberta, October 30, 2024--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2024 before markets open on November 7, 2024.

Aurinia’s management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update.

Webcast & Conference Call Details

The link to the audio webcast is available here. To join the conference call, please dial (800) 715-9871 / +1 (646) 307-1963. Conference ID: 6251719 or company name required for entry. A replay of the webcast will be available on Aurinia’s website.

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS^® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).

View source version on businesswire.com: https://www.businesswire.com/news/home/20241030222492/en/

Contacts

Media & Investor Inquiries:
Andrea Christopher
Corporate Communications & Investor Relations
Aurinia Pharmaceuticals Inc.
achristopher@auriniapharma.com

General Investor Inquiries:
ir@auriniapharma.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2479974750"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2479974750\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2479974750?lang=zh_TW&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OLSNBVyd5G4ZtpkRpRDugA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/58fdc57fe1de779c255ac2278dd13d7c","is_english":true,"pubTime":"2024-10-31 04:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2479974750","market":"us","top_or_hot":-1,"title":"Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"512\" src=\"https://s.yimg.com/uu/api/res/1.2/W7E2NSDIgA1dbcQ7YD0ecw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/58fdc57fe1de779c255ac2278dd13d7c\" title=\"\" width=\"1024\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>ROCKVILLE, Md. &amp; EDMONTON, Alberta, October 30, 2024</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/AUPH\">Aurinia Pharmaceuticals Inc</a>. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2024 before markets open on November 7, 2024.</p>\n<p>Aurinia’s management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update.</p>\n<p><b>Webcast &amp; Conference Call Details</b></p>\n<p>The link to the audio webcast is available here. To join the conference call, please dial (800) 715-9871 / +1 (646) 307-1963. Conference ID: 6251719 or company name required for entry. A replay of the webcast will be available on Aurinia’s website.</p>\n<p><b>About Aurinia</b></p>\n<p>Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS<sup>®</sup> (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20241030222492/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>Media &amp; Investor Inquiries: </b><br/>Andrea Christopher<br/>Corporate Communications &amp; Investor Relations<br/>Aurinia Pharmaceuticals Inc.<br/><b>achristopher@auriniapharma.com </b><b><br/></b><br/><b>General Investor Inquiries: </b><br/><b>ir@auriniapharma.com</b><br/><br/><br/><br/><br/><br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Business Wire</strong><span class=\"h-time small\">2024-10-31 04:05</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body>\n<figure>\n<img border=\"0\" height=\"512\" src=\"https://s.yimg.com/uu/api/res/1.2/W7E2NSDIgA1dbcQ7YD0ecw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/58fdc57fe1de779c255ac2278dd13d7c\" title=\"\" width=\"1024\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>ROCKVILLE, Md. &amp; EDMONTON, Alberta, October 30, 2024</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/AUPH\">Aurinia Pharmaceuticals Inc</a>. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2024 before markets open on November 7, 2024.</p>\n<p>Aurinia’s management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update.</p>\n<p><b>Webcast &amp; Conference Call Details</b></p>\n<p>The link to the audio webcast is available here. To join the conference call, please dial (800) 715-9871 / +1 (646) 307-1963. Conference ID: 6251719 or company name required for entry. A replay of the webcast will be available on Aurinia’s website.</p>\n<p><b>About Aurinia</b></p>\n<p>Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS<sup>®</sup> (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20241030222492/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>Media &amp; Investor Inquiries: </b><br/>Andrea Christopher<br/>Corporate Communications &amp; Investor Relations<br/>Aurinia Pharmaceuticals Inc.<br/><b>achristopher@auriniapharma.com </b><b><br/></b><br/><b>General Investor Inquiries: </b><br/><b>ir@auriniapharma.com</b><br/><br/><br/><br/><br/><br/></p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/aurinia-pharmaceuticals-release-third-quarter-200500525.html\">Business Wire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AUPH","symbol_name":"Aurinia Pharmaceuticals Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/aurinia-pharmaceuticals-release-third-quarter-200500525.html","article_id":"2479974750","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OLSNBVyd5G4ZtpkRpRDugA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/58fdc57fe1de779c255ac2278dd13d7c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479974750","pubTimestamp":1730318700,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"ROCKVILLE, Md. & EDMONTON, Alberta, October 30, 2024----Aurinia Pharmaceuticals Inc.   today announced that it will release financial and operational results for the third quarter of 2024 before markets open on November 7, 2024.Aurinia’s management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update.The link to the audio webcast is available here. To join the conference call, please dial  715-9871 / +1  307-1963. Conference ID: 6251719 or company name required for entry. A replay of the webcast will be available on Aurinia’s website.Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS , the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differen","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AUPH":"Aurinia Pharmaceuticals Inc","BK4139":"生物科技"},"translate_title":"Aurinia Pharmaceuticals将于2024年11月7日发布第三季度财务和运营业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUPH":1},"content_text":"ROCKVILLE, Md. & EDMONTON, Alberta, October 30, 2024--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2024 before markets open on November 7, 2024.\nAurinia’s management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update.\nWebcast & Conference Call Details\nThe link to the audio webcast is available here. To join the conference call, please dial (800) 715-9871 / +1 (646) 307-1963. Conference ID: 6251719 or company name required for entry. A replay of the webcast will be available on Aurinia’s website.\nAbout Aurinia\nAurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).\nView source version on businesswire.com: https://www.businesswire.com/news/home/20241030222492/en/\nContacts\nMedia & Investor Inquiries: Andrea ChristopherCorporate Communications & Investor RelationsAurinia Pharmaceuticals Inc.achristopher@auriniapharma.com General Investor Inquiries: ir@auriniapharma.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}